Radiopharmaceuticals - A US and European Market Analysis

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW
A Quick Primer
Key Market Trends
Continuous Battle Against Cancer: A Key Driver for Growth
Cancer Statistics: A Grim Prognosis
Business Case for Radiopharmaceuticals Exemplified
Development of Newer Diagnostic Agents to Boost Growth
Demographics & New Applications Offer Opportunities On a Platter
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
Widespread Awareness Among Practitioners & Patients: The Need of the Hour
Expansion of Molecular Imaging Platform is Key to Future Growth
Molecular Imaging Agents: A Noteworthy Breakthrough
Growing Demand for PET to Drive Up Demand
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth
Manufacturers Quick to Take Cue
Promising Developments in Therapeutic Radiopharmaceuticals Underway
Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic Radiopharmaceuticals
International Collaborations Give a Thumbs Up to Drug Development
Market Challenges
High Costs of Drug Development Piques Manufacturers
Supply Shortages: A Niggling Cause of Concern
Price Sensitivity & Competition from Alternatives Limit Market Potential
Lack of Dosage Standards for Pediatric Patients’ Limits Radiopharmaceutical Efficacy
Unfounded Fears of Radiation Exposure Hinder Growth
Bottlenecks in Developing Markets
Market Share Statistics: In Retrospect
3.PRODUCT FACTS
A. Diagnostic Radiopharmaceuticals
B. Therapeutic Radiopharmaceuticals
4.REGIONAL MARKET OVERVIEW
i.The United States
ii.Europe
ii(a).France
ii(b).Germany
ii(c).Italy
ii(d).The United Kingdom
ii(e).Spain
ii(f).Rest of Europe
5.RESEARCH & DEVELOPMENT BREAKTHROUGHS
Azaya, Texas University Collaborate for Liposomal Radiation Therapy
Pharmacyclics Reveals Phase 1/2 Study of MGd Antibody Targeted Radiation Therapy
Peregrine Explores Potential of Cotara® for Brain Cancer Treatment
Scientists Develop New Manufacturing Technology For Cancer Diagnostic Radioisotopes
Avid Radiopharmaceuticals Exploits ExpIND to Speed AD Drug Research
Scientists Commend Combination Therapy for Follicular Lymphoma Patients
Missouri University Develops New Cancer Radiotherapy Method
AGH Researchers Develop New Radioactive Seed Therapy for Lung Cancer
AnazaoHealth® Obtains US Patent for Novel Radiopharmaceutical Preparations
INMAS Develops Ciprofloxacin Radiolabelling Kit
6.CORPORATE DEVELOPMENTS
Positron Concludes Dose Shield Acquisition
Positron Licenses NuView to Sell Imaging Technologies and Dose Dispensing Devices
Bracco Imaging, Marillion Pharmaceuticals to Develop Novel Cancer Treatment
EUSA Pharma Concludes Cytogen Acquisition
AMIC, CRS to Co-Produce Indium-111
AMIC, MU Partner to Produce Radioisotopes
Bracco, Lantheus to Co-Promote CardioGen-82®
Cell Therapeutics Submits sBLA for Use of Zevalin® in First-Line Therapy
Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging Kit
GE Healthcare Gets FDA Nod For New PET/CT Scanner
GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal
CIS-US Receives FDA Approval for Generic Choletec® Kit
Cellectar Obtains Funds for Clinical Trials
Lantheus Medical Completes Phase I Study of Novel PET Imaging Tracer
GE Healthcare, Cardinal Health Partner for Myoview™ Imaging Agent
Avista Capital Partners Acquires Medical Imaging Unit of Bristol-Myers
Siemens Healthcare Opens Two Radiopharmacies in US
Cardinal Health Plans to Offer Services to Support PET Clinical Trials
MEDRAD Associates with PETNET to Ingeniously Deliver FDG
Triad Isotopes to Build Four Nuclear Pharmacies
AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals
Cardinal Health Expands Manufacturing Capabilities for PET Imaging Agents
Jubilant Completes Draxis Acquisition
IBA Plans to Acquire CIS BIO
Ion Beam Announces Closure of TAEK Financing
IBA Receives Approval for New Radiopharmaceutical Production Facility in UK
Ion Beam Partners with Lantheus to Distribute Neurolite®, Cardiolite® in Europe
EIS Eczacibasi to Acquire 50 Percent Stake in Monrol
Siemens to Set up Multiple Radiopharmaceutical Facilities in India
Siemens Plans to Establish Its First Molecular Imaging Centre in India
Bayer and FutureChem Enter Radiolabeling Technology Licensing Agreement
Medrad Mounts Intego™ PET Infusion System at UPMC
IBA Molecular Announces the Launch of Cyclone ® 18 Twin
Immunomedics Announces Pre-Clinical Results for its Combination Radioimmunotherapy
Molecular Insight Develops New Radioiodinated Molecules
Immunomedics Develops New Antibody for Radioimmunotherapy
Triad Acquires Four Radiopharmaceutical Companies
Triad Isotopes Acquires Regional Nuclear Pharmacies
Triad Isotopes Merges with Diversified Pharmacy Group
Molecular Insight Pharmaceuticals Acquires Radiopharmaceutical Facility In Texas
GE Healthcare to Shelf Production of Products with Short-Lived Radioisotopes
Cell Therapeutics Acquires Zevalin® Lymphoma Drug
Premier Signs Contracts with Mallinckrodt, Agfa, Berlex
ADMD Announces Patent Licensing for Preparing Actinium-225
Bayer Schering Exercises Rights to License Avid's 18-F AV1/ZK Compound
Covidien Signs Agreement with BioSynthema for Cancer Treatment Technology
IBA Signs Contract to Supply Cyclone® 30 to Indian DAE
MDS Nordion, Ottawa University to Establish Molecular Imaging Center of Excellence
Bracco, ImaRx Ink Cross Licensing Deal
GE Healthcare Signs Exclusive Distribution Deal with Draximage
DRAXIMAGE, Med Discovery Form Research Collaboration
Schering Changes Corporate Identity to Bayer Schering Pharma AG
IBA Establishes New Radiopharmaceuticals Production Facility
IBA Receives Approval for Production of Radiopharmaceuticals at UK Facility
IBA Establishes Production and R&D Center in Belgium
MDS Nordion to Expand Medical Imaging Agent Production in Europe
MDS Nordion, Avid Radiopharmaceuticals Ink Collaborative Agreement
MDS Nordion Establishes Centers of Excellence for TheraSphere® in Europe
Peregrine Opens Facility in China
GE Healthcare Receives Approval for First Radiopharmacy Facility in India
Peregrine Pharmaceuticals Launches Anti-Cancer Agent in China
GE Healthcare Introduces Proton Package For Radiation Therapy Planning
GE Healthcare Expands Definium Series of Digital Radiographic Products
7.MAJOR PLAYERS
Actinium Pharmaceuticals, Inc. (US)
Advanced Medical Isotope Corporation (US)
Alseres Pharmaceuticals, Inc (US)
Bayer HealthCare Pharmaceuticals (US)
Bio-Nucleonics, Inc. (US)
Bracco Diagnostics, Inc. (US)
Cardinal Health, Inc (US)
Cellectar, LLC. (US)
Cell Therapeutics, Inc. (US)
Covidien Imaging Solutions (US)
Cytogen Corporation (US)
Draximage Inc (Canada)
GE Healthcare Limited (UK)
GlaxoSmithKline Plc (UK)
IBA Molecular North America, Inc. (US)
Immunomedics, Inc. (US)
Kimberly-Clark, Inc. (US)
Lantheus Medical Imaging, Inc (US)
MDS Nordion (Canada)
Molecular Insight Pharmaceuticals, Inc. (US)
Peregrine Pharmaceuticals, Inc. (US)
PETNET Pharmaceuticals, Inc. (US)
Pharmalucence, Inc. (US)
Triad Isotopes, Inc. (US)
Table 1: Percentage Share Breakdown of Leading Medical Diagnostics Imaging Manufacturer Value Sales in the World –
Table 2: Percentage Revenue Market Shares of Leading Radiopharmaceutical Medical Diagnostics Manufacturers in the World –
Table 3: Percentage Share Breakdown of Radioimmunotherapy Products Manufacturer Value Sales in the World –
Table 4: Breakdown of Diagnostic Radiopharmaceutical Agents Procedure Volume by Imaging Procedure in the US –
Table 5: Percentage Share Breakdown of Diagnostic Radiopharmaceutical Agents in the US –
Table 6: Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent in the US –
Table 7: Percentage Share Breakdown of Non-Cardiology Diagnostic Radiopharmaceuticals Agent Manufacturer Value Sales in the US –
Table 8: Installed Base for SPECT and SPECT/CT Scanners in Units in the North American Diagnostic Radiopharmaceutical Market for Years 2008, 2010, 2012 &
Table 9: Breakdown of FDG Procedure Volume by Procedure Type – 2009 (In 000s)
Table 10: US FDG Radiopharmacy Market: Number of Doses, Unit Cost and Number of Nuclear Pharmacies for the Years 2008 & 2009 2012(P)
Table 11: Percentage Share Breakdown of Leading Diagnostics Radiopharmaceuticals Agents Manufacturer Value Sales in the US –
Table 12: Percentage Share Breakdown of Leading Cardiology Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales in the US –
Table 13: Percentage Share Breakdown of Leading Non-Cardiology Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales in the US –
Table 14: Percentage Share Breakdown of Therapeutic Radiopharmaceuticals Manufacturer Value Sales by Key Radiotherapeutics in the US –
Table 15: Percentage Share Breakdown of Leading Therapeutic Radiopharmaceutical Agents Manufacturer Value Sales in the US –
Table 16: Percentage Share Breakdown of Leading FDG Manufacturers by Number of Cyclotrons Operated in the US –
Table 17: Percentage Share Breakdown of Radiopharmaceutical Bone Palliation Procedures by Key Radiotherapeutics in the US –
Table 18: Percentage Share Breakdown of Leading Diagnostics Radiopharmaceuticals Manufacturer Value Sales in the US –
Table 19: Percentage Share Breakdown of Leading Cardiology Diagnostics Radiopharmaceuticals Manufacturer Value Sales in the US –
Table 20: Percentage Share Breakdown of Leading Therapeutic Radiopharmaceuticals Manufacturer Value Sales in the US –
Table 21: Percentage Share Breakdown of Leading Radiopharmaceuticals Manufacturer Value Sales by Diagnostic Procedures in the US –
Table 22: Percentage Breakdown of Radiopharmacy Market in the US –
Table 23: Percentage Share Breakdown of Leading Radiopharmacies Manufacturer Value Sales in the US –
Table 24: Radiopharmaceuticals Market by Segment in the US: 2007-2015 (Sales in US$ Million)
Table 25: Percentage Breakdown of Radiopharmaceuticals Market by Segment in the US for the Years 2009 &
Table 26: Percentage Share Breakdown of Diagnostic Radiopharmaceuticals by Imaging Modalities in Europe – 2008 &
Table 27: Radiopharmaceuticals Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Radiopharmaceuticals Market by Region in Europe for the Years 2009 &
Table 29: Radiopharmaceuticals Market by Segment in Europe: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Radiopharmaceuticals Market by Segment in Europe for the Years 2009 &
Table 31: Radiopharmaceuticals Market by Segment in France: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Radiopharmaceuticals Market by Segment in France for the Years 2009 &
Table 33: Radiopharmaceuticals Market by Segment in Germany: 2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Radiopharmaceuticals Market by Segment in Germany for the Years 2009 &
Table 35: Radiopharmaceuticals Market by Segment in Italy: 2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Radiopharmaceuticals Market by Segment in Italy for the Years 2009 &
Table 37: Radiopharmaceuticals Market by Segment in the UK: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Radiopharmaceuticals Market by Segment in the UK for the Years 2009 &
Table 39: Radiopharmaceuticals Market by Segment in Spain: 2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of Radiopharmaceuticals Market by Segment in Spain for the Years 2009 &
Table 41: Radiopharmaceuticals Market by Segment in Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of Radiopharmaceuticals Market by Segment in Rest of Europe for the Years 2009 &
Companies Profiled